Infection Treatment Biotech Ruthigen Files for a $27 Million IPO

Published: Aug 12, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Ruthigen, a biotech developing therapeutics to prevent and treat infection in surgical and trauma procedures, filed on Thursday with the SEC to raise up to $27 million in an initial public offering. The Santa Rosa, CA-based company, which was founded in 2013, plans to list on the NASDAQ under the symbol RTGN.

Help employers find you! Check out all the jobs and post your resume.

Back to news